

# Public Health

## IOWA HHS

Kim Reynolds  
GOVERNOR

Adam Gregg  
LT. GOVERNOR

Kelly Garcia  
DIRECTOR

**Date: October 2, 2023**

**To: Iowa Vaccines for Children (VFC) Program Providers**

**From: Iowa VFC Program**

**Re: Vaccine Update: Nirsevimab (Beyfortus)**

---

Effective October 2, 2023, the Iowa VFC Program will implement and allow ordering of Nirsevimab (Beyfortus).

Nirsevimab (Beyfortus) is a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) among infants aged <8 months born during or entering their first RSV season and infants and children 8-19 months who are at increased risk for severe RSV disease and entering their second RSV season.

A detailed summary is available on the [VFC Program Website](#) and includes information on use, dosage, schedule, and contraindications.

### **VFC Ordering:**

Due to the anticipated limited allocation of Beyfortus, clinics should order small quantities initially. This will allow initial uptake to be determined and will prevent possible wastage. Based on limited inventory, it may be necessary for the Program to reduce provider orders. Please order smaller quantities of Beyfortus initially until uptake of this product is identified which will prevent possible wastage.

VFC Available Vaccines and Covered Age Ranges documents are available on the [VFC Program Website](#).

If you have questions regarding recommendations for use of Nirsevimab contact Shelly Jensen RN BSN at 1-800-831-6293 ext. 2. For questions regarding vaccine orders contact the VFC Program at 1-800-831-6293 ext. 6.